A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

(2015) Caroline Bonner et al.   NATURE MEDICINE

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

(2014) David ZI Cherney et al.   Cardiovascular Diabetology

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

(2014) Bowen Lin et al.   Cardiovascular Diabetology

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Metformin Supports the Antidiabetic Effect of a Sodium Glucose Cotransporter 2 Inhibitor by Suppressing Endogenous Glucose Production in Diabetic Mice

(2014) Susanne Neschen et al.   DIABETES

Adverse effects and safety of SGLT-2 inhibitors

(2014) S. Halimi et al.   DIABETES & METABOLISM

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

(2014) Bruce A. Perkins et al.   DIABETES CARE

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

(2014) Ilkka Tikkanen et al.   DIABETES CARE

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

(2014) Marko Škrtić et al.   DIABETOLOGIA

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Public health: Society at large

(2014) Tony Scully   NATURE

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

(2014) Matthias Oelze et al.   PLoS One

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

(2014) Steven P Vickers et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

(2013) Arne Ring et al.   Cardiovascular Diabetology

Sodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular Hyperfiltration

(2013) Robert C. Stanton   CIRCULATION

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis

(2013) Sayaka Maeda et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors

(2013) S. Cangoz et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data

(2013) Eiji Kurosaki et al.   PHARMACOLOGY & THERAPEUTICS

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?

(2013) Usha Panchapakesan et al.   PLoS One

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

(2013) Shigeto Kanada et al.   Journal of Diabetes Investigation

SGLT inhibitors in management of diabetes

(2013) Abd A Tahrani et al.   Lancet Diabetes & Endocrinology

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

(2013) Tim Heise et al.   Diabetes Therapy

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

(2012) G. Luippold et al.   DIABETES OBESITY & METABOLISM

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

(2012) Akiko Sarashina et al.   Drug Metabolism and Pharmacokinetics

Diabetes in numbers

(2012) Tony Scully   NATURE

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

Chances and risks of SGLT2 inhibitors

(2012) Peter Mayer   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion

(2011) V. Gorboulev et al.   DIABETES

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

(2011) Michael J. Jurczak et al.   DIABETES

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

(2011) L. Thomas et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

(2011) Muhammad A. Abdul-Ghani et al.   ENDOCRINE REVIEWS

Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter

(2011) Rolf Grempler et al.   FEBS LETTERS

The Sweet Pee Model for Sglt2 Mutation

(2011) J. P. Ly et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

(2011) James F. List et al.   KIDNEY INTERNATIONAL

SGLT2 inhibitors: molecular design and potential differences in effect

(2011) Masayuki Isaji   KIDNEY INTERNATIONAL

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2010) Volker Vallon et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule

(2010) V. Vallon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target

(2009) R. Santer et al.   Clinical Journal of the American Society of Nephrology

Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis

(2009) G. M. Magee et al.   DIABETOLOGIA

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2008) Wei Meng et al.   JOURNAL OF MEDICINAL CHEMISTRY